Enjoy complimentary customisation on priority with our Enterprise License!
The global travel vaccines market size is estimated to grow by USD 3.97 billion at a CAGR of 8.64% between 2023 and 2028. The market is driven by several factors, including a surge in global migration, increased awareness of vaccine-preventable diseases among travelers, and mandatory regulations requiring immunization before visa issuance. These elements collectively propel market growth, reflecting the intersection of public health initiatives, travel trends, and regulatory frameworks. The surge in global migration underscores the rising movement of people across borders, necessitating robust immunization measures. Simultaneously, heightened awareness of vaccine-preventable diseases among travelers highlights the importance of vaccinations in preventing outbreaks. Additionally, mandatory immunization regulations for visa issuance ensure compliance with health standards, further supporting market expansion. Thus, the interplay of these factors shapes the landscape for the anticipated growth of the travel vaccination market.
A key dimension of globalization is the rapid increase in the number of cross-border travelers. The awareness of vaccine-preventable diseases has increased in the past few years among travelers. Awareness of vaccine-preventable diseases among travelers mainly relates to the knowledge of the infections prevailing in the country that they are visiting, as well as knowledge about the key options available to prevent such diseases. Moreover, factors that determine the rate of uptake of medicine among travelers include the length of the trip, the age of the traveler, the purpose of travel, social class, and the purpose of the trip. For instance, if the purpose of the travel is to visit friends and relatives, it is less likely that the traveler would seek pre-travel health advice. Hence, the increasing awareness related to vaccination among people across the globe before traveling is expected to increase the demand for several medicines, especially travel vaccines, which, in turn, is expected to drive the growth of the market during the forecast period.
To learn more about this report, Request Free Sample
The market share growth by the influenza segment will be significant during the forecast period. The incidence of influenza is rising and is expected to rise further during the forecast period. In recent years, high rates of influenza-associated hospitalization have been seen in many countries.
Get a glance at the market contribution of various segments Download PDF Sample
The influenza segment was the largest and was valued at USD 3.34 billion in 2018. The market for influenza is projected to show significant growth owing to the growing demand for influenza vaccines by the end-user facilities coupled with the rise in the traveling rate. However, the viral product in the influenza vaccine must be a good antigenic match for the strain of the virus prevalent in the destination to which the person is going. Also, influenza medicine may not protect the person against all winter-related respiratory infections across the globe. Thus, the rising incidence of influenza globally will drive the demand for medicine, which, in turn, will boost the growth of the influenza segment of the market during the forecast period.
Adult vaccines are chemicals recommended for individuals who are 18 years of age or older. These chemicals protect against infectious diseases that can be contracted at any age and can have serious consequences for adults. Some common adult chemicals include those for tetanus, diphtheria, pertussis (Tdap), influenza, pneumococcal disease, hepatitis A and B, and shingles. Vaccination before travel can reduce the risk of contracting these diseases and protect travelers from serious illness or even death. In addition to protecting the individual adult, adult chemicals also help prevent the spread of infectious diseases and protect public health. Thus, with the growing traveling activities globally, the demand for adult vaccines will increase, which, in turn, will boost the growth of the adult vaccines segment of the market during the forecast period.
Pediatric vaccines held the highest share of the market in 2023 and are an important aspect of healthcare for children and adolescents, particularly those who may be traveling to areas with a high risk of infectious diseases. These are designed to protect children against a variety of diseases such as measles, mumps, rubella measles, mumps, rubella, polio, hepatitis A and B, typhoid fever, and yellow fever which can be easily spread through close contact with infected individuals or contaminated surfaces and which can cause serious illness or even death in some cases. In addition to protecting the individual child, pediatrics also helps prevent the spread of infectious diseases and protect public health. Such wide benefits of pediatric medicines will drive their use and the growth of the pediatric vaccines segment of the global market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America will continue to dominate the market during the forecast period. The presence of government bodies like the Pan American Health Organization (PAHO), which provides recommended immunization schedules for vaccination, plays a crucial role in shaping the market in the region. The major vaccines sold in North America were BOOSTRIX, INFANRIX, Pediarix, BEXSERO, MENVEO, and influenza vaccines. The prevalence of several infectious as well as non-infectious diseases has been increasing at a significant rate in developed countries of the region over the past few years. For instance, in the US, the prevalence of influenza increases majorly during November and remains at high levels for several weeks from January to February every year.
In addition, the region is witnessing increasing access to vaccines against such diseases and a growing number of initiatives to generate awareness about immunization programs. Furthermore, immigrant visa applicants in the US are required to meet the immunization requirements for certain diseases. The World Health Organization (WHO) and CDC recommend vaccination for travelers to the US against diseases such as rabies, hepatitis A and B, measles, mumps and rubella, diphtheria, pneumonia, and influenza. Hence, the growing demand for immunization before traveling to countries in the region is expected to foster the growth of the market in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Bharat Biotech Ltd. - The company offers travel vaccines such as BioHib, a lyophilized vaccine that is used for development based on an Indian strain.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is witnessing significant growth due to an increase in costs for vaccination and a rising number of vaccines developed through advanced recombinant DNA technology and mRNA vaccines technology. The use of vaccinations among travellers is essential to prevent diseases caused by attenuated organisms. The likelihood of disease exposure during travel drives the demand for travel vaccines. Industry gains are fueled by innovations and the growing awareness of the need for vaccinations among travellers.
Mandatory regulations on immunization prior to issuing visas are notably driving the market growth. The Market is experiencing notable growth propelled by the implementation of mandatory regulations on immunization prior to issuing visas. Governments worldwide are enacting stringent measures to curb the international spread of travel-related diseases by mandating vaccination against diseases like yellow fever, typhoid, Japanese encephalitis, diphtheria, and cholera. In adherence to immigration laws and regulations, countries such as the United States require immigrants to undergo mandatory screening for infectious diseases and obtain age-dependent vaccination coverage before an immigration visa is granted. Vaccination against prevalent diseases like Hepatitis A and B, polio, and others is obligatory, and failure to comply may lead to visa application rejection or additional scrutiny.
Additionally, various countries like Cambodia, the Central African Republic, and China demand travelers to present a yellow fever vaccination certificate as a prerequisite for entry. Organizations such as the CDC provide travelers with comprehensive guidelines on vaccine-preventable diseases and respective federal regulations to ensure compliance. These mandatory vaccination regulations underscore the importance of preventive measures against infectious diseases and significantly contribute to the growth of the Travel Vaccines Market by fostering heightened demand for vaccination services and products.
Increased incidence of travel-related diseases is an emerging trend shaping the market growth. Traveling is often associated with higher health risks, especially infectious diseases. The incidence of travel-related diseases such as Hepatitis A and E, meningitis, yellow fever, typhoid, Japanese encephalitis, diphtheria, and cholera is increasing worldwide. Hence, travelers and travel medicine practitioners need to be aware of the epidemiology of infectious diseases in the destination country. The major strategies that could be adopted include avoiding travel to regions with recent outbreaks and epidemics.
In addition to the destination, the duration and season of travel may also contribute to the risk of acquiring a travel-related infection. Therefore, the increase in the incidence of travel-related diseases will lead to more investments in the global market for the development of more effective vaccines, and hence, will propel the growth of the market during the forecast period.
The high cost is a significant challenge hindering market growth. The high cost also poses a challenge for travelers to get vaccinated for travel-related diseases. The average first-time traveler requires about 2-3 vaccinations. Travel clinics often offer vaccinations at slightly higher prices, and new vaccines are usually the most expensive. The high cost is an important factor that discourages travelers from being fully immunized prior to travel. Travelers may perceive certain vaccines as not essential, and hence, their unwillingness to pay for the cost of these vaccines might be a barrier. Also, for travelers like students and volunteers intending to travel, the high cost may pose a barrier to getting themselves immunized.
Moreover, the use of combined vaccines against travel-associated diseases may lead to a reduction in the overall cost of vaccination as well as the number of injections required. Thus, initiatives are being undertaken to assure travelers that the cost of the vaccine outweighs the healthcare-related expenses that they will incur if they are infected with the disease. This, in turn, may limit the adoption to a certain extent and thereby is expected to hamper the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Vaccines Market: Vaccines Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast
Travel Technologies Market: Travel Technologies Market Analysis North America, Europe, APAC, Middle East and Africa, South America - US, China, India, UK, Germany - Size and Forecast
Online Travel Agencies IT Spending Market: Online Travel Agencies IT Spending Market Analysis North America, Europe, APAC, South America, Middle East and Africa - US, Canada, China, Germany, UK - Size and Forecast
The market is witnessing significant growth due to various factors such as patient epidemiology, the increase in cases of flu, and rising travel and tourism activities globally. With the surge in global arrivals of foreign visitors, there's a growing concern for travel safety, leading to a rising demand for specialized vaccines. Vaccines such as diphtheria pertussis tetanus (DPT) are increasingly being developed using advanced technologies like recombinant DNA and mRNA vaccines, leveraging biotechnology to combat pathogens and prevent disease prevalence. The World Health Organization (WHO) recommends the use of international certificates of vaccination or prophylaxis (ICVP) for overseas travelers, adding to the substantial cost involved in vaccination.
First-time travelers often incur consultation fees and administration charges for multiple doses required to achieve complete immunization before embarking on vacations or engaging in medical tourism. Travel vaccines target a range of microbes, including attenuated and pathogenic organisms, to provide immunity against health hazards prevalent in different regions. Despite concerns about side effects and dosages, advancements in vaccine formulations, novel vaccine technologies, and molecular genetics are driving the development of safer and more effective travel vaccinations. Key players in the pharmaceutical industry, such as Dyanavax, are investing in research and development to introduce innovative vaccines like HEPLISAV B for diseases like Hepatitis B virus and DUKORAL for diarrhea prevention. As healthcare infrastructure continues to improve, the travel vaccines market is expected to expand further, catering to the increasing demand for preventive healthcare measures among travelers worldwide.
Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.64% |
Market Growth 2024-2028 |
USD 3.97 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
7.7 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 43% |
Key countries |
US, Germany, UK, Japan, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Altimmune Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., CSL Ltd., Dynavax Technologies Corp., Emergent BioSolutions Inc., GlaxoSmithKline Plc, KM Biologics Co. Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., SK Chemicals Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE |
Market dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Disease Type
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.